top of page
News, Events and Updates
Search
Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease
Jan 13
Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology
Jan 8
Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program
Jan 6
Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion
Dec 18, 2025
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
Dec 12, 2025
Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Nov 26, 2025
Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update
Nov 25, 2025
Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference
Nov 19, 2025
Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025
Nov 18, 2025
1
2
3
4
5
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
